观察雷公藤多苷联合咪唑斯汀治疗皮炎湿疹的疗效和安全性分析(1)
[摘要] 目的 探讨雷公藤多苷联合咪唑斯汀治疗皮炎湿疹的临床效果，并分析其安全性。方法 方便选取该院2013年11月—2015年11月期间所收治的265例皮炎湿疹患者作为该次研究对象，按照计算机表法将其分为实验组(n=135)和参照组(n=130)，参照组患者应用咪唑斯汀缓释片治疗，实验组应用雷公藤多苷联合咪唑斯汀缓释片治疗，对比分析两组患者的临床疗效，并比较两组患者的不良反应发生情况。结果 实验组总有效率为95.55%，参照组总有效率为85.38%(χ2=8.018 5，P=0.004 6)；治疗前，两组症状积分差异无统计学意义，治疗后，实验组症状积分明显低于参照组，治疗后3周，实验组症状积分为(2.11±1.59)分，参照组为(5.51±1.89)分，组间差异有统计学意义；实验组不良反应发生率为2.22%，参照组不良反应发生率为7.69%，组间差异有统计学意义(χ2=4.247 8，P=0.039 3)。结论 雷公藤多苷与咪唑斯汀联合治疗皮炎湿疹的临床效果显著，具有较高的安全性，值得应用。
[关键词] 雷公藤多苷；咪唑斯汀；C-反应蛋白；皮炎湿疹
[中图分类号] R4 [文献标识码] A [文章编号] 1674-0742(2018)05(b)-0117-03
[Abstract] Objective This paper tries to explore the clinical efficacy of Tripterygium glycosides combined with mizolastine in the treatment of dermatitis and eczema， and to analyze its safety. Methods 265 cases of dermatitis and eczema patients admitted in this hospital from November 2013 to November 2015 were selected as the study object and were divided into experimental group (n=135) and reference group (n=130) according to the computer table method. The patients in the reference group were treated with mizolastine sustained release tablets. The experimental group was treated with triptolide and mizolastine sustained release tablets. The clinical efficacy of the two groups of patients was analyzed and compared， and the incidence of adverse reactions was compared between the two groups of patients. Results The total effective rate in the experimental group was 95.55%， the total effective rate in the reference group was 85.38%(χ2=8.018 5， P=0.004 6)；before treatment， there was no significant difference in symptom scores between the two groups. After treatment， the symptom scores in the experimental group were significantly lower. In the reference group， at 3 weeks after treatment， the symptom scores in the experimental group was (2.11±1.59)points， and the reference group was (5.51±1.89)points. The difference between the groups was significant； the incidence of adverse reactions in the experimental group was 2.22%， and the adverse reaction rate in the reference group was 7.69%. there was a statistically significant difference between the groups(χ2=4.247 8， P=0.039 3). Conclusion The combination of tripterygium glycosides and mizolastine in the treatment of dermatitis and eczema has a significant clinical effect and a high safety， and is worthy of application.
[Key words] Tripterygium glycosides； Mizolastine； C-reactive protein； Dermatitis eczema
皮炎濕疹属于皮肤科常见症状之一，临床主要表现在：顽固难治与反复发作[1]，目前，治疗该病症的方法多采用局部糖皮质激素，但是不良反应较多，且患者的免疫功能明显下降，停药后复发率较高[2-3]，基于此，该文就对H1受体拮抗药物咪唑斯汀与雷公藤多苷治疗的临床疗效进行探讨，选取病例为该院2013年11月—2015年11月收治的265例皮炎湿疹患者，现报道如下。, http://www.100md.com(刘民厚)
[关键词] 雷公藤多苷；咪唑斯汀；C-反应蛋白；皮炎湿疹
[中图分类号] R4 [文献标识码] A [文章编号] 1674-0742(2018)05(b)-0117-03
[Abstract] Objective This paper tries to explore the clinical efficacy of Tripterygium glycosides combined with mizolastine in the treatment of dermatitis and eczema， and to analyze its safety. Methods 265 cases of dermatitis and eczema patients admitted in this hospital from November 2013 to November 2015 were selected as the study object and were divided into experimental group (n=135) and reference group (n=130) according to the computer table method. The patients in the reference group were treated with mizolastine sustained release tablets. The experimental group was treated with triptolide and mizolastine sustained release tablets. The clinical efficacy of the two groups of patients was analyzed and compared， and the incidence of adverse reactions was compared between the two groups of patients. Results The total effective rate in the experimental group was 95.55%， the total effective rate in the reference group was 85.38%(χ2=8.018 5， P=0.004 6)；before treatment， there was no significant difference in symptom scores between the two groups. After treatment， the symptom scores in the experimental group were significantly lower. In the reference group， at 3 weeks after treatment， the symptom scores in the experimental group was (2.11±1.59)points， and the reference group was (5.51±1.89)points. The difference between the groups was significant； the incidence of adverse reactions in the experimental group was 2.22%， and the adverse reaction rate in the reference group was 7.69%. there was a statistically significant difference between the groups(χ2=4.247 8， P=0.039 3). Conclusion The combination of tripterygium glycosides and mizolastine in the treatment of dermatitis and eczema has a significant clinical effect and a high safety， and is worthy of application.
[Key words] Tripterygium glycosides； Mizolastine； C-reactive protein； Dermatitis eczema
皮炎濕疹属于皮肤科常见症状之一，临床主要表现在：顽固难治与反复发作[1]，目前，治疗该病症的方法多采用局部糖皮质激素，但是不良反应较多，且患者的免疫功能明显下降，停药后复发率较高[2-3]，基于此，该文就对H1受体拮抗药物咪唑斯汀与雷公藤多苷治疗的临床疗效进行探讨，选取病例为该院2013年11月—2015年11月收治的265例皮炎湿疹患者，现报道如下。, http://www.100md.com(刘民厚)
参见：首页 > 中医药 > 中药专业 > 中草药汇编 > 中药大典 > 全草类 > 雷公藤